Ardelyx, Inc.

Symyx Technologies, Inc.

Relypsa, Inc.

Rhone-poulenc Chimie

Ilypsa, Inc.

Rhodia Chimie

Jsr Corporation

Vifor (international) Ltd.

Conopco, Inc.

Unilever Home and Personal Care Usa, Division of Conopco, Inc.

Rhodia Limited

Rhone-poulenc Films

Raisio Chemicals Oy

Dominique Charmot

Han-Ting Chang

Han Ting Chang

Mingjun Liu

Jeffrey William Jacobs

Gerrit Klaerner

Eric F Connor

Christopher Carreras

Michael Robert Leadbetter

Noah Bell

Eric Labonte

Marc Navre

Jerry M Buysse

Jason Gustaf Lewis

Michael James Cope

Paul Mansky

Futian Liu

Florence Roger

Tao Chen

Didier G Benoit

John Fordtran

Samir Z Zard

Nicholas Reich

Jun Shao

Ingrid Langsetmo

Robert C Blanks

James Prentice Davidson

Fangling Lin

Natalia Blinova

Pascale Corpart

Tony Kwok-Kong Mong

Kenji Okamoto

Yan Chen

Ralph B Nielsen

Adam Luke Safir

Isao Nishimura

Kalpesh N Biyani

Yong Wang

Yunxiao Li

Deidre Madsen

Wilfried Blokzijl

Son Hoai Nguyen

Manikandan Jayaraman

Jonathan Mills

Damian A Hajduk

Ezat Khoshdel

Mathias Destarac

Marcelo Eduardo Piotti

Angela Lee

Laura T Mazzola

Peter Huefner

Robert Alpern

Miroslav Petro

Bernd Jandeleit

Jean M J Frechet

Victor Oswaldo Nava-Salgado

Wenyue Wang

Jean-Francois Fiard

William Bett

Xavier Franck

Ghenwa Bouhadir

Vincent Granier

Nicole Oger

Isabelle Gauthier-Gillaizeau

Tomasz W Glinka

Gilles Guerin

Bruno Langlois

Jean-Claude Daniel

Thibaud Biadatti

Leo Zhaoqing Liu

Roland Reeb

Eric James Connor

Robert John Carswell

Yvette Girardeau

Giovanni Francesco Unali

Andrew Richard Avery

Akimasa Soyano

Jean M J Fr&eacute;chet

Pierre Grosjean

Gerard Berrod

Gilbert Schorsch

Robert Alan Hunter

Elizabeth Goka

Detlef Albrecht

Michael Burdick

Werner Strüver

Shiah-yun Chen

Dominic Wai Kwing Yeung

Heinz Viehe

Christine Vidil

Srinivas Nomula

Bruno Amram

Mathias Agnely

Bruno Drochon

Phil D Armitage

Eve Pere

Daniel Michelet

Ramakrishnan Chidambaram

Robert Gresser

Sherin Halfon

The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders. The methods generally comprise administering to a mammal in need thereof a pharmaceutically effective amount of a compound, or a pharmaceutical composition comprising such a compound, that is designed to be substantially active in the gastrointestinal (GI) tract to inhibit NHE-mediated antiport of sodium ions and hydrogen ions therein. More particularly, the method comprises administering to a mammal in need thereof a pharmaceutically effective amount of a compound, or a pharmaceutical composition comprising such a compound, that inhibits NHE-3, -2 and/or -8 mediated antiport of sodium and/or hydrogen ions in the GI tract and is designed to be substantially impermeable to the layer of epithelial cells, or more specifically the epithelium of the GI tract. As a result of the compound being substantially impermeable, it is not absorbed and is thus essentially systemically non-bioavailable, so as to limit the exposure of other internal organs (e.g., liver, heart, brain, etc.) thereto. The present disclosure is still further directed to a method wherein a mammal is administered such a compound with a fluid-absorbing polymer, such that the combination acts as described above and further provides the ability to sequester fluid and/or salt present in the GI tract.

Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders

Provided are non-NHE3-binding agents having activity as phosphate transport/uptake inhibitors in the gastrointestinal tract, including in the small intestine, methods for their use as therapeutic or prophylactic agents, and related methods of drug discovery.

Compounds and methods for inhibiting phosphate transport

Provided are NHE3-binding and/or NHE3-modulating agents having activity as phosphate transport inhibitors, including inhibitors of phosphate transport in the gastrointestinal tract and the kidneys, and methods for their use as therapeutic or prophylactic agent.

NHE3-binding compounds and methods for inhibiting phosphate transport

The present invention provides methods and compositions for the treatment of ion imbalances using core-shell composites and compositions comprising such core-shell composites. In particular, the invention provides core-shell particles and compositions comprising potassium binding polymers, and core-shell particles and compositions comprising sodium binding polymers, and in each case, pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are also disclosed. The compositions and methods of the invention offer improved approaches for treatment of hyperkalemia and other indications related to potassium ion homeostasis, and for treatment of hypertension and other indicates related to sodium ion homeostasis.

Methods and compositions for selectively removing potassium ion from the gastrointestinal tract of a mammal

The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising potassium binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hyperkalemia, such as hyperkalemia caused by renal failure and/or the use of hyperkalemia causing drugs.

Ion binding polymers and uses thereof

The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders.

The present invention is directed to compositions and methods of removing potassium or treating hyperkalemia by administering pharmaceutical compositions of cation exchange polymers with low crosslinking for improved potassium excretion and for beneficial physical properties to increase patient compliance.

Compositions and methods for treating hyperkalemia

Pharmaceutical compositions for treating hyperkalemia

Growing community of inventors

Campbell, CA, United States of America

Dominique Charmot